R
ReNAgade Therapeutics
Revolutionizing RNA medicine with integrated delivery, coding, editing, and insertion technologies to precisely correct diseases
About ReNAgade Therapeutics
ReNAgade Therapeutics is a biotechnology startup that operates in the field of RNA medicine. The company's main goal is to overcome the current limitations of RNA medicines, which include delivery to tissue targets and the lack of an integrated therapeutic platform. To achieve this, ReNAgade has developed a proprietary toolkit that allows them to precisely correct diseases on a large scale.
Read full description
The company's business model revolves around the use of its proprietary delivery technologies to unlock previously inaccessible cells. This is achieved by reprogramming cells with superior expression using the leading RNA coding platform, in a joint venture with Orna Therapeutics.
ReNAgade's approach is unique in that it aims to enable curative therapies by permanently correcting defective genes with its proprietary technology. This is a significant step forward in the field of gene therapy, which traditionally involves the insertion of healthy genes into cells to replace defective ones.
The company's technology also allows for the insertion of exons or large genes, positioning it as a leader in the Gene Therapy 2.0 platform. This means that ReNAgade is not just treating symptoms, but is working to cure diseases at their genetic root.
ReNAgade operates in the biotechnology market, serving clients in the medical and healthcare sectors who are seeking innovative solutions to complex health problems. The company generates revenue through its joint ventures, licensing its proprietary technologies, and potentially through the development and sale of its own therapeutic products.
At a glance
- Status
- Acquired
- Founded
- 2021
- Headquarters
- Cambridge, United States
- Employees
- 24
- Open positions
- None listed
- Dealroom signal
- 25.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Rumoured $1B, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning ReNAgade Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | May 2024 | $0 | — | Orna Therapeutics | ↗ |
| SERIES AOther financing | May 2023 | $300M | $1.2B | MPM BioImpact · F2 Ventures | ↗ |
Growth signals
Latest recorded traffic for ReNAgade Therapeutics is 540 monthly website visits, down 34.1% over the last three months. ReNAgade Therapeutics's team declined 76.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
MPM BioImpact- FVF2 Ventures
Other known investors1 additional known investor
Orna Therapeutics
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ReNAgade Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ReNAgade Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.